Skip to main content

Table 3 Multivariable model and clinical score generation from the derivation dataset (N = 2838)

From: Risk scores for predicting early antiretroviral therapy mortality in sub-Saharan Africa to inform who needs intensification of care: a derivation and external validation cohort study

  Predictor—model A (excluding CD4) Predictor—model B (including CD4)
AOR 95% CI p value ß coefficient Score AOR 95% CI p value ß coefficient Score
Sex and pregnancy status Female (pregnant) 1.00 0 1.00 0
Female (non-pregnant) 1.94 (0.58–6.50) 0.283 0.66 1 1.71 (0.53–5.52) 0.373 0.53 1
Male 3.54 (0.95–13.26) 0.060 1.26 2 2.93 (0.82–10.44) 0.097 1.08 2
Number of WHO TB symptoms 0 1.00 0 1.00 0
≥ 1 3.65 (2.24–5.97) < 0.001 1.30 2 3.33 (2.06–5.38) < 0.001 1.20 2
WHO stage I/II 1.00 0 1.00 0
III/IV 2.72 (1.42–5.20) 0.003 1.00 2 2.55 (1.32–4.92) 0.005 0.94 2
Temperature at enrollment ≤ 37.5 °C 1.00 0 1.00 0
> 37.5 °C 3.39 (1.65–6.96) 0.001 1.22 2 3.37 (1.56–7.26) 0.002 1.21 2
CD4 count ≥ 200/μL N/A 1.00 0
< 200/μL N/A 2.05 (1.20–3.50) 0.009 0.72 1
Anemia statusa No anemia 1.00 0 1.00 0
Mild/moderate anemia 5.03 (2.57–9.87) < 0.001 1.62 2 4.58 (2.37–8.84) < 0.001 1.52 3
Severe anemia 9.42 (3.43–25.89) < 0.001 2.24 3 8.02 (3.04–21.14) < 0.001 2.08 4
  1. Abbreviations: AOR adjusted odds ratio, CI confidence interval, WHO World Health Organization
  2. aAnemia severity was classified according to World Health Organization criteria as follows: no anemia, hemoglobin level of ≥ 13.0 g/dL for men, ≥ 12.0 g/dL for non-pregnant females, and ≥ 11.0 g/dL for pregnant females; mild/moderate anemia, 8.0 to < 13.0 g/dL for men, 8.0 to < 12.0 g/dL for non-pregnant women, and 7.0 to < 11.0 g/dL for pregnant women; and severe anemia, < 8.0 g/dL for males and non-pregnant females and < 7.0 g/dL for pregnant women